SEC Form 4 · accession 0001574774-19-000005
BIOTELEMETRY, INC. · BEAT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Heather C Getz
Officer — Executive VP & CFO
Period of report
Jan 25, 2019
Accepted (ET)
Jan 29, 2019 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001574774
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 25, 2019 | M | 38,524 | $2.54 | A | 119,085 | D | |
| Common Stock | Jan 25, 2019 | M | 26,465 | $2.80 | A | 145,550 | D | |
| Common StockF2 | Jan 25, 2019 | S | 64,989 | $70.09 | D | 80,561 | D | |
| Common Stock | Jan 28, 2019 | M | 28,194 | $2.80 | A | 108,755 | D | |
| Common StockF3 | Jan 28, 2019 | S | 28,194 | $70.00 | D | 80,561 | D | |
| Common Stock | Jan 29, 2019 | M | 200 | $2.80 | A | 80,761 | D | |
| Common Stock | Jan 29, 2019 | S | 200 | $70.00 | D | 80,561 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F5,F4 | $2.54 | Jan 25, 2019 | M | 38,524 | D | — | Feb 19, 2023 | Common Stock | 38,524 | 0 | D |
| Stock Options (Right to Buy)F6 | $2.80 | Jan 25, 2019 | M | 26,465 | D | — | Feb 21, 2022 | Common Stock | 26,465 | 38,984 | D |
| Stock Options (Right to Buy)F6 | $2.80 | Jan 28, 2019 | M | 28,194 | D | — | Feb 21, 2022 | Common Stock | 28,194 | 10,790 | D |
| Stock Options (Right to Buy)F6 | $2.80 | Jan 29, 2019 | M | 200 | D | — | Feb 21, 2022 | Common Stock | 200 | 10,590 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.66, inclusive. The reporting person undertakes to provide to BioTelemetry, Inc., any security holder of BioTelemetry, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and footnote 3 to this Form 4.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $70.00 to $70.11, inclusive.
- F4The stock options vested in four equal annual installments, which began on December 31, 2013. The options were fully exercisable as of December 31, 2016.
- F5The reporting person's Form 4 filed on February 21, 2012, reporting this grant of options overreported the options by 748 shares. Therefore, the Form 4 filed on January 23, 2019, overreported 748 shares in Column 9.
- F6The stock options vested in four equal annual installments, which began on December 31, 2012. The options were fully exercisable as of December 31, 2015.